VALUATING CLINICAL APPLICATIONS OF LIQUID BIOPSY BY COMBINING CIRCULATING TUMOR DNA AND TUMOR CELLS

Vishnu P. Tripathi, M. K. Aneebuddin, C. Alex, Keshav Moharir
{"title":"VALUATING CLINICAL APPLICATIONS OF LIQUID BIOPSY BY COMBINING CIRCULATING TUMOR DNA AND TUMOR CELLS","authors":"Vishnu P. Tripathi, M. K. Aneebuddin, C. Alex, Keshav Moharir","doi":"10.24092/crps.2021.110403","DOIUrl":null,"url":null,"abstract":"\"Liquid biopsy\" concentrates on the identification of ‘Circulating Tumor Cells (CTC) as well as ‘Cell-free Tumor DNA’ (ctDNA) in the systemic circulation of individuals suffering from cancer, has received a lot of interest due to its evident clinical implications for individualized therapy. CTC and ctDNA studies have created fresh diagnostic approaches and are now the foundations of liquid biopsy. The existing study concentrates on cancer diagnoses, prognosis prediction in people having treatable diseases, observing systemic therapy, and patient categorization depending on the identification of aimed therapeutics or resistance mechanisms. Although the use of CTCs and ctDNA for initial cancer diagnosis is gaining popularity, existing techniques experience major challenges in terms of particularity and sensitivity. Prognosis projection in people with the treatable disease so far realized in some cancer entities, especially in breast cancer. Sequential assessments of CTCs or ctDNA can also be used to monitor the progress or non-success of systemic medicines (such as hormone and chemotherapy as well as various targeted therapies).To integrate liquid diagnostic tests into personalized medicine, interventional studies on therapy stratification based on CTC and ctDNA analyses are required. KEYWORDS: Tumor cells, DNA, Circulating cells, Chemotherapy, Liquid biopsy","PeriodicalId":11053,"journal":{"name":"Current Research in Pharmaceutical Sciences","volume":"56 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24092/crps.2021.110403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

"Liquid biopsy" concentrates on the identification of ‘Circulating Tumor Cells (CTC) as well as ‘Cell-free Tumor DNA’ (ctDNA) in the systemic circulation of individuals suffering from cancer, has received a lot of interest due to its evident clinical implications for individualized therapy. CTC and ctDNA studies have created fresh diagnostic approaches and are now the foundations of liquid biopsy. The existing study concentrates on cancer diagnoses, prognosis prediction in people having treatable diseases, observing systemic therapy, and patient categorization depending on the identification of aimed therapeutics or resistance mechanisms. Although the use of CTCs and ctDNA for initial cancer diagnosis is gaining popularity, existing techniques experience major challenges in terms of particularity and sensitivity. Prognosis projection in people with the treatable disease so far realized in some cancer entities, especially in breast cancer. Sequential assessments of CTCs or ctDNA can also be used to monitor the progress or non-success of systemic medicines (such as hormone and chemotherapy as well as various targeted therapies).To integrate liquid diagnostic tests into personalized medicine, interventional studies on therapy stratification based on CTC and ctDNA analyses are required. KEYWORDS: Tumor cells, DNA, Circulating cells, Chemotherapy, Liquid biopsy
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
循环肿瘤DNA与肿瘤细胞结合液体活检的临床应用价值评价
“液体活检”专注于识别癌症患者体循环中的循环肿瘤细胞(CTC)和“无细胞肿瘤DNA”(ctDNA),由于其明显的个体化治疗临床意义而受到广泛关注。CTC和ctDNA的研究创造了新的诊断方法,现在是液体活检的基础。现有的研究集中在癌症诊断、可治疗疾病患者的预后预测、观察全身治疗以及根据确定靶向治疗或耐药机制对患者进行分类。尽管使用CTCs和ctDNA进行早期癌症诊断越来越受欢迎,但现有技术在特殊性和敏感性方面面临重大挑战。可治疗疾病患者的预后预测目前已在一些癌症实体中实现,特别是在乳腺癌中。CTCs或ctDNA的序贯评估也可用于监测全身药物(如激素和化疗以及各种靶向治疗)的进展或失败。为了将液体诊断测试整合到个性化医疗中,需要基于CTC和ctDNA分析的治疗分层介入研究。关键词:肿瘤细胞,DNA,循环细胞,化疗,液体活检
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
EVALUATION OF IN VIVO ANTI-ACNE ACTIVITY OF FLOWER EXTRACT OF WITHANIA COAGULANS FORMULATION AND EVALUATION OF PHYTOSOMES LOADED WITH PITHECELLOBIUM BIJENINUM LEAF EXTRACT FORMULATION AND EVALUATION OF GASTRO-RETENTIVE MICROSPHERE OF SAXAGLIPTIN ANTIDIABETIC AGENT ISOLATION AND IDENTIFICATION OF ACTINOMYCETES WITH ANTIBACTERIAL ACTIVITY FROM SOIL SAMPLES AROUND KANDY, SRI LANKA DEVELOPMENT AND CHARACTERIZATION OF GAMMA ORYZANOL LOADED NIOSOMES
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1